

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

September 18, 2017

To,

BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

Subject: Updated Financials for quarter ended June 2017


Dear Sir / Madam,

With reference to the above captioned subject we enclose the revised Financials for the quarter ended June 2017; pursuant to Regulation 33 of SEBI Listing Regulations, 2015 and Section 133 read with Schedule III of Companies Act, 2013.

Kindly take the same on your Records.

Thanking you,


For **FREDUN PHARMACEUTICALS LIMITED**



DIRECTOR

Office Address : Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA)
Phone : 91-22 – 4031 8111 Fax : 91-22-40318133 E-mail : business@fredungroup.com Web : www.fredungroup.com

Factory Address : 14,15,16, Zorabian Industrial Complex, Veoor, Palghar (E) , Dist: Palghar - 401 404.
Phone : 91- 2525- 253194 Fax No: 91- 2525-253193



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

FREDUN PHARMACEUTICALS LTD.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THREE MONTHS ENDED
30 Jun 17

NO	PARTICULARS	Quarter ended			Rs. in Lacs
		30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
1	Income from Operations				
	Net Sales /IncomeFrom Operation (Net of Excise Duty)	914.94	1735.65	1649.90	5669.62
2	Other Operating Income	15.33	31.40	17.57	191.38
3	Total income from operators (net)	930.27	1767.05	1667.47	5861.00
4	Expenses				
	a) Cost of Material Consumed	704.44	891.98	809.22	3395.85
	b) Purchases of stock -in-trade	0.00	0.00	0.00	23.68
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(119.24)	175.35	426.58	298.35
	d)Finance Costs	36.11	60.87	37.90	187.48
	e) Emploess benefits expenses	96.26	152.31	99.57	491.82
	f) Depreciation and amortisation expenses	22.39	48.19	20.11	113.58
	g) Other Expenses	145.28	327.64	198.37	1125.26
	Total Expenditure	885.24	1656.34	1591.75	5636.02
5	Profit/(Loss) from ordinary activities before exceptional items & tax (3+4)	45.03	110.71	75.72	224.98
6	Exceptional items / Prior Period Item	0.00	0.00	0.00	(2.39)
7	Profit/(Loss) from ordinary activities before tax (5-6)	45.03	110.71	75.72	222.59
8	Tax Expenses	8.00	67.85	15.00	79.85
9	Profit/(Loss) from continuing operations	37.03	42.86	60.72	142.74
10	Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax Expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00
13	Profit/ (Loss) for the period	37.03	42.86	60.72	142.74
14	Other comprehensive Income				
	A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00
	B (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00
15	Paid up Equity Share Capital (Face Value of Rs-10/- each)	237.45	237.45	237.45	237.45
16	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	238.55
17	Earning per Share (EPS) for continuing operations - Basic	1.56	1.81	2.56	6.01
	- Diluted	1.56	4.37	2.56	6.11
	Earning per Share (EPS) for discontinuing operations - Basic	0.00	0.00	0.00	0.00
	- Diluted	0.00	0.00	0.00	0.00
	Earning per Share (EPS) for continuing and discontinuing operations - Basic	1.56	1.81	2.56	6.01
	- Diluted	1.56	4.37	2.56	6.11
	Basic/ Diluted Earning Per Share (Rs.) (for continuing and discontinued operations)	1.56	1.81	2.56	6.01
A	1) Public Shareholding				
	Number of shares	601290	601290	601290	601290
	Percentage of shareholding	25.56	25.56	25.56	25.56
	2) Promoters and promotor group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-
	- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	1751110	1751110	1751110	1751110
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%	100%
	- Percentage of shares (as a % of total share capital of the Company)	74.44	74.44	74.44	74.44

NOTES:-


- The above results were taken on record by the Board Of Directors at the meeting held on 11.08.2017
- Previous year's figures have been regrouped/rearranged wherever necessary.
- During the quarter ended 30th June 2017 there are no investor's complaints pending & no investor's complaints were received by the company during this period.
- Provision for deferred tax as applicable will be made at the end of the year
- Dividend on Preference shares will be considered at the year end.
- The above result have already been approve by the Audit Committee of the board

Office Address : Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA)

Phone : 91-22 – 4031 8111 Fax : 91-22-40318133 E-mail : business@fredungroup.com Web : www.fredungroup.com

Factory Address : 14,15,16, Zorabian Industrial Complex, Veoor, Palghar (E), Dist: Palghar - 401 404.

Phone : 91- 2525- 253194 Fax No: 91- 2525-253193



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

7) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April, 2016.

8) Employee Benefit Expense

Particulars	Quarter ended			Year ended
	30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
Salary & Wages	75.29	119.05	74.93	391.56
Director Remuneration	12.30	12.30	12.30	49.20
Contribution to Provident and Other Funds	4.06	9.99	3.34	26.32
Share Base Payment to employees	0.00	0.00	0.00	0.00
Staff Welfare Expenses	2.74	5.37	3.34	17.52

9) Gain/ Loss on account of Foreign Exchange Fluctuation (Included in other Income)

Particulars	Quarter ended			Year ended
	30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
Gain / Loss on Account of Foreign Exchange	0.78	6.73	0.00	6.73

10) Reconciliation of Net Profit between Previous GAAP and IND AS

	Quarter ended 30.06.2017		
	I- GAAP	Effect of transition to IND AS	IND -AS
Income from Operations			
Net Sales /IncomeFrom Operation (Net of Excise Duty)	914.94	-	914.94
Other Operating Income	15.33	-	15.33
Total income from operations (net)	930.27	-	930.27
Expenses			
a) Cost of Material Consumed	704.44	-	704.44
b) Purchases of stock -in-trade	0.00	-	0.00
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(119.24)	-	(119.24)
d) Finance Costs	36.11	-	36.11
e) Employess benefits expenses	96.26	-	96.26
f) Depreciation and amortisation expenses	22.39	-	22.39
g) Other Expenses	145.28	-	145.28
Total Expenditure	885.24	-	885.24
Profit/(Loss) from ordinary activities before exceptional items & tax (3+4)	45.03	-	45.03
Exceptional items / Prior Period Item	0.00	-	0.00
Profit/(Loss) from ordinary activities before tax (5-6)	45.03	-	45.03
Tax Expenses	8.00	-	8.00
Profit/(Loss) from continuing operations	37.03	-	37.03
Profit/(Loss) from discontinued operations	0.00	-	0.00
Tax Expense of discontinued operations	0.00	-	0.00
Profit/(Loss) from discontinued operations after tax	0.00	-	0.00
Profit/ (Loss) for the period	37.03	-	37.03
Other comprehensive Income	0.00	-	0.00
Total Comprehensive Income for the period	37.03	-	37.03

PLACE: MUMBAI

DATE : 11.08.2017


FOR FREDUN PHARMACEUTICALS LIMITED

D. Medhan
DIRECTOR.

Office Address : Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA)
Phone : 91-22 – 4031 8111 Fax : 91-22-40318133 E-mail : business@fredungroup.com Web : www.fredungroup.com

Factory Address : 14,15,16, Zorabian Industrial Complex, Veoor, Palghar (E), Dist: Palghar - 401 404.

Phone : 91- 2525- 253194 Fax No: 91- 2525-253193



Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W) MUMBAI - 400 031.

PHONE : 24102526, 24112526

FAX : 24132121

LIMITED REVIEW REPORT

TO THE BOARD OF DIRECTORS OF FREDUN PHARMACEUTICALS LTD

26,Manoj Industries Premises,
G.P.Ambekar marg, Wadala,
Mumbai – 400 031.

1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended June 30, 2017 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other recognized accounting policies to the extent applicable, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MUMBAI, August 11, 2017

FOR SAVLA & ASSOCIATES
Chartered Accountants
(Firm Registration No.109361W)

DEEPAK G. SAVLA
(Partner)

Membership No. : 043901